Table 4 Recent patents on nano-based ocular drug delivery systems
From: Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Patent title/description | Patent no | Disease targeted | Year | References |
|---|---|---|---|---|
Seed crystal nanoparticles tetrandrine ophthalmic formulation and preparation method | CN105726484B | Cataract | 2016 | [350] |
Puerarin and scutellarin lipid nanoparticle ophthalmic preparation and preparation method thereof | CN108066315A | Cataract | 2016 | [351] |
Timolol maleate cubic liquid crystal nanoparticle eye drops and preparation method thereof | CN106619573A | Improved corneal infiltration capacity | 2016 | [352] |
Ophthalmic nanoemulsion composition containing cyclosporin and method for preparing same | PH12015502587B1 | Dry eye disease | 2016 | [353] |
Cyclosporine containing nonirritative nanoemulsion ophthalmic composition | US 9,320,801 B2 | Dry eye disease | 2016 | [354] |
Nanosuspension of tobramycin and dexamethasone and preparation method thereof | CN105708844A | DED, Conjunctivitis, and tingling sensation in the eye | 2016 | [355] |
Treatment of glaucoma and/or retinal diseases | WO2017152129A2 | Glaucoma and retinal diseases | 2017 | [356] |
Method for regulating retinal endothelial cell viability | US 9,566,255 | Pathological conditions of retinal endothelial cells | 2017 | [357] |
Pharmaceutical nanoparticles showing improved mucosal transport | AU2013256092B2 | Aid in the transportation of Low aqueous soluble drugs in front of the eye | 2017 | [358] |
Nanoparticle ophthalmic composition for the treatment of ocular disorders or diseases | US20190070242A1 | Tear dysfunction syndrom | 2018 | [359] |
Non-irritating nanoemulsion eye drop composition containing cyclosporine | US 15/747,618 | Dry eye disease | 2018 | [360] |
Method for regulating retinal endothelial cell viability | US 10,010,516 t | Pathological conditions of retinal endothelial cell | 2018 | [361] |
Compositions of jasmonate compounds and methods of use | US20180000958 A1 | Angiogenesis-related | 2018 | [362] |
Ophthalmic compositions and methods of use | US20190008920A1 | Disorders, inflammatory diseases | 2018 | [363] |
Liposomes that contain at least one bilayer of lipid a prostaglandin F2α and phosphatidylcholine | US9956195B2 | Dry eye syndrome | 2018 | [364] |
A nanostructured biocompatible wafer which was used in conjuctival cul-de-sac | US9931306B2 | Glaucoma, ocular surface disease | 2018 | [365] |
The NPs, implants and microparticles are formed by the combination of polymer-drug | US20190070302A1 | Wet AMD, uveitis | 2019 | [366] |
Nanoparticles stabilized by nitrophenylboronic acid composition | JP2019108372A | For effective delivery of drugs to specific targets of eyes | 2019 | [367] |
Drug delivery implant for treating eye diseases, and preparation method | WO2019160306A1 | Ocular surface diseases | 2019 | [368] |
Liposome corticosteroid for the locally injecting in inflammation lesion or region | CN109906075A | Inflammatory lesion in eye | 2019 | [369] |
An oil-in-water nanoemulsion composition of clobetasol | WO2018233878A1 | Inflammatory diseases or conditions | 2019 | [370] |
Ophthalmic compositions and methods of use | WO2020047197A1 | Dry eye disease related symptoms | 2020 | [371] |
Eye composition containing cyclosporine and a method of preparing the same | KR20200000395A | Dry eye disease, conjunctivitis, and tingling sensation in the eye | 2020 | [372] |
A surfactant-free type ophthalmic nanoemulsion composition and the manufacturing method thereo | KR20200053205A | Dry eye disease | 2020 | [373] |
Nanocrystalline eye drop, preparation method, and application thereof | CN110664757A | Congenital macular degeneration | 2020 | [374] |
Preservative free ocular compositions and methods for using same for treating dry eye disease and other eye disorders | US10751337B2 | Dry eye disease and other eye disorders | 2020 | [375] |